Market Closed -
Nasdaq
21:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.55
USD
|
0.00%
|
|
+18.32%
|
-15.76%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
535.1
|
143
|
175.9
|
166.5
|
176.1
|
-
|
-
|
Enterprise Value (EV)
1 |
500.7
|
120.3
|
157.9
|
166.5
|
176.1
|
176.1
|
176.1
|
P/E ratio
|
-3.11
x
|
-3.35
x
|
-1.48
x
|
-2.88
x
|
-4.27
x
|
-5.6
x
|
-11.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
11.7
x
|
2.62
x
|
4.6
x
|
3.39
x
|
2.62
x
|
2.18
x
|
1.76
x
|
EV / Revenue
|
11.7
x
|
2.62
x
|
4.6
x
|
3.39
x
|
2.62
x
|
2.18
x
|
1.76
x
|
EV / EBITDA
|
-26,712,242
x
|
-3,786,195
x
|
-3,744,196
x
|
-4,379,344
x
|
-
|
-
|
-
|
EV / FCF
|
-
|
-4.69
x
|
-3.64
x
|
-
|
-3.42
x
|
-12.7
x
|
-50.3
x
|
FCF Yield
|
-
|
-21.3%
|
-27.4%
|
-
|
-29.2%
|
-7.89%
|
-1.99%
|
Price to Book
|
13
x
|
8.26
x
|
8.66
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,541
|
27,027
|
76,496
|
90,476
|
113,628
|
-
|
-
|
Reference price
2 |
20.16
|
5.290
|
2.300
|
1.840
|
1.550
|
1.550
|
1.550
|
Announcement Date
|
16/03/21
|
14/03/22
|
06/03/23
|
01/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
24.55
|
45.56
|
54.51
|
38.21
|
49.09
|
67.3
|
80.63
|
100.1
|
EBITDA
|
-
|
-20.03
|
-37.76
|
-46.99
|
-38.01
|
-
|
-
|
-
|
EBIT
1 |
-
|
-22.93
|
-40.94
|
-50.59
|
-41.34
|
-38.9
|
-29.21
|
-
|
Operating Margin
|
-
|
-50.34%
|
-75.11%
|
-132.39%
|
-84.22%
|
-57.8%
|
-36.23%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-31.35
|
-43.16
|
-65.45
|
-52.15
|
-41.7
|
-31.4
|
-20.6
|
Net income
1 |
-30.73
|
-31.35
|
-43.16
|
-65.45
|
-52.15
|
-41.7
|
-33.41
|
-20.6
|
Net margin
|
-125.15%
|
-68.81%
|
-79.18%
|
-171.27%
|
-106.23%
|
-61.96%
|
-41.44%
|
-20.58%
|
EPS
2 |
-21.31
|
-6.480
|
-1.580
|
-1.550
|
-0.6400
|
-0.3633
|
-0.2767
|
-0.1400
|
Free Cash Flow
1 |
-
|
-
|
-30.46
|
-48.27
|
-
|
-51.5
|
-13.9
|
-3.5
|
FCF margin
|
-
|
-
|
-55.89%
|
-126.32%
|
-
|
-76.52%
|
-17.24%
|
-3.5%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/10/20
|
16/03/21
|
14/03/22
|
06/03/23
|
01/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
7.224
|
6.548
|
10.95
|
11.11
|
9.608
|
9.056
|
11.87
|
13.49
|
14.67
|
14.82
|
16.4
|
17.45
|
18.6
|
18.25
|
19.4
|
EBITDA
|
-10.82
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.68
|
-14.38
|
-11.63
|
-10.61
|
-13.89
|
-16.37
|
-10.93
|
-7.172
|
-6.87
|
-11.02
|
-9
|
-9.4
|
-9.5
|
-
|
-
|
Operating Margin
|
-161.67%
|
-219.61%
|
-106.17%
|
-95.53%
|
-144.56%
|
-180.8%
|
-92.04%
|
-53.16%
|
-46.84%
|
-74.38%
|
-54.88%
|
-53.87%
|
-51.08%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.28
|
-15.59
|
-15.82
|
-13.7
|
-20.34
|
-18.7
|
-13.36
|
-10.95
|
-9.139
|
-13.61
|
-11.1
|
-8.9
|
-8.1
|
-12.2
|
-8.6
|
Net income
1 |
-13.28
|
-15.59
|
-15.82
|
-13.7
|
-20.34
|
-18.7
|
-13.36
|
-10.95
|
-9.139
|
-13.61
|
-11.1
|
-8.9
|
-8.1
|
-12.2
|
-8.6
|
Net margin
|
-183.86%
|
-238.03%
|
-144.51%
|
-123.34%
|
-211.67%
|
-206.52%
|
-112.5%
|
-81.16%
|
-62.31%
|
-91.87%
|
-67.68%
|
-51%
|
-43.55%
|
-66.85%
|
-44.33%
|
EPS
2 |
-0.4900
|
-0.5000
|
-0.4000
|
-0.3400
|
-0.3500
|
-0.2400
|
-0.1700
|
-0.1400
|
-0.1000
|
-0.1400
|
-0.0900
|
-0.0733
|
-0.0667
|
-0.1100
|
-0.0750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/03/22
|
11/05/22
|
04/08/22
|
03/11/22
|
06/03/23
|
11/05/23
|
07/08/23
|
07/11/23
|
01/03/24
|
08/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
34.4
|
22.7
|
18
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-30.5
|
-48.3
|
-
|
-51.5
|
-13.9
|
-3.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-142%
|
-325%
|
-414%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
1.550
|
0.6400
|
0.2700
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.95
|
2.24
|
3.3
|
-
|
9.6
|
7.6
|
8.4
|
Capex / Sales
|
-
|
4.27%
|
4.11%
|
8.63%
|
-
|
14.26%
|
9.43%
|
8.39%
|
Announcement Date
|
02/10/20
|
16/03/21
|
14/03/22
|
06/03/23
|
01/03/24
|
-
|
-
|
-
|
Last Close Price
1.55
USD Average target price
3.25
USD Spread / Average Target +109.68% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.76% | 176M | | -17.08% | 8.39B | | +54.07% | 3.74B | | -37.54% | 2.55B | | -9.63% | 2.48B | | -13.43% | 2.32B | | -4.20% | 1.93B | | -18.24% | 1.6B | | -36.41% | 1.28B | | +2.19% | 1.08B |
Medical & Diagnostic Laboratories
|